Nicolaes GA, Dahlbäck B (febrero de 2003). «Congenital and acquired activated protein C resistance». Semin. Vasc. Med.3 (1): 33-46. PMID15199491. doi:10.1055/s-2003-38331.
Eichacker PQ, Natanson C, Danner RL (19 de octubre de 2006). «Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.». The New England Journal of Medicine355 (16): 1640-2. PMID17050887. doi:10.1056/NEJMp068197.
Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF (13 de abril de 2011). «Human recombinant activated protein C for severe sepsis». En Martí-Carvajal, Arturo J, ed. Cochrane database of systematic reviews (Online) (4): CD004388. PMID21491390. doi:10.1002/14651858.CD004388.pub4.
Mosnier LO, Griffin JH (2006). «Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities». Front. Biosci.11: 2381-99. PMID16720321. doi:10.2741/1977.
Kisiel W, Canfield WM, Ericsson LH, Davie EW (diciembre de 1977). «Anticoagulant properties of bovine plasma protein C following activation by thrombin». Biochemistry16 (26): 5824-31. PMID588557. doi:10.1021/bi00645a029.
Kisiel W, Ericsson LH, Davie EW (noviembre de 1976). «Proteolytic activation of protein C from bovine plasma». Biochemistry15 (22): 4893-900. PMID990250. doi:10.1021/bi00667a022.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (mayo de 1994). «Mutation in blood coagulation factor V associated with resistance to activated protein C». Nature369 (6475): 64-7. PMID8164741. doi:10.1038/369064a0.
PROWESS: recombinant Human Activated PROtein C Worldwide Evaluation in Severe Sepsis; Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (marzo de 2001). «Efficacy and safety of recombinant human activated protein C for severe sepsis». N. Engl. J. Med.344 (10): 699-709. PMID11236773. doi:10.1056/NEJM200103083441001.
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (junio de 2002). «Activation of endothelial cell protease activated receptor 1 by the protein C pathway». Science296 (5574): 1880-2. PMID12052963. doi:10.1126/science.1071699.
Gu JM, Crawley JT, Ferrell G, Zhang F, Li W, Esmon NL, Esmon CT (noviembre de 2002). «Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality». J. Biol. Chem.277 (45): 43335-43. PMID12218060. doi:10.1074/jbc.M207538200.
Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF (13 de abril de 2011). «Human recombinant activated protein C for severe sepsis». En Martí-Carvajal, Arturo J, ed. Cochrane database of systematic reviews (Online) (4): CD004388. PMID21491390. doi:10.1002/14651858.CD004388.pub4.
Eichacker PQ, Natanson C (marzo de 2007). «Increasing evidence that the risks of rhAPC may outweigh its benefits». Intensive Care Med.33 (3): 396-9. PMID17325833. doi:10.1007/s00134-007-0556-8.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (septiembre de 2005). «Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death». N. Engl. J. Med.353 (13): 1332-41. PMID16192478. doi:10.1056/NEJMoa050935.
Vehar GA, Davie EW (febrero de 1980). «Preparation and properties of bovine factor VIII (antihemophilic factor)». Biochemistry19 (3): 401-10. PMID7356933. doi:10.1021/bi00544a001.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (junio de 2008). «Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)». Chest133 (6 Suppl): 160S-198S. PMID18574265. doi:10.1378/chest.08-0670.
Nicolaes GA, Dahlbäck B (febrero de 2003). «Congenital and acquired activated protein C resistance». Semin. Vasc. Med.3 (1): 33-46. PMID15199491. doi:10.1055/s-2003-38331.
Eichacker PQ, Natanson C, Danner RL (19 de octubre de 2006). «Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.». The New England Journal of Medicine355 (16): 1640-2. PMID17050887. doi:10.1056/NEJMp068197.
Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF (13 de abril de 2011). «Human recombinant activated protein C for severe sepsis». En Martí-Carvajal, Arturo J, ed. Cochrane database of systematic reviews (Online) (4): CD004388. PMID21491390. doi:10.1002/14651858.CD004388.pub4.
Mammen EF, Thomas WR, Seegers WH (diciembre de 1960). «Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A)». Thromb. Diath. Haemorrh.5: 218-49. PMID13765990.
Mosnier LO, Griffin JH (2006). «Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities». Front. Biosci.11: 2381-99. PMID16720321. doi:10.2741/1977.
Kisiel W, Canfield WM, Ericsson LH, Davie EW (diciembre de 1977). «Anticoagulant properties of bovine plasma protein C following activation by thrombin». Biochemistry16 (26): 5824-31. PMID588557. doi:10.1021/bi00645a029.
Kisiel W, Ericsson LH, Davie EW (noviembre de 1976). «Proteolytic activation of protein C from bovine plasma». Biochemistry15 (22): 4893-900. PMID990250. doi:10.1021/bi00667a022.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (mayo de 1994). «Mutation in blood coagulation factor V associated with resistance to activated protein C». Nature369 (6475): 64-7. PMID8164741. doi:10.1038/369064a0.
PROWESS: recombinant Human Activated PROtein C Worldwide Evaluation in Severe Sepsis; Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (marzo de 2001). «Efficacy and safety of recombinant human activated protein C for severe sepsis». N. Engl. J. Med.344 (10): 699-709. PMID11236773. doi:10.1056/NEJM200103083441001.
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (junio de 2002). «Activation of endothelial cell protease activated receptor 1 by the protein C pathway». Science296 (5574): 1880-2. PMID12052963. doi:10.1126/science.1071699.
Gu JM, Crawley JT, Ferrell G, Zhang F, Li W, Esmon NL, Esmon CT (noviembre de 2002). «Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality». J. Biol. Chem.277 (45): 43335-43. PMID12218060. doi:10.1074/jbc.M207538200.
Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF (13 de abril de 2011). «Human recombinant activated protein C for severe sepsis». En Martí-Carvajal, Arturo J, ed. Cochrane database of systematic reviews (Online) (4): CD004388. PMID21491390. doi:10.1002/14651858.CD004388.pub4.
Eichacker PQ, Natanson C (marzo de 2007). «Increasing evidence that the risks of rhAPC may outweigh its benefits». Intensive Care Med.33 (3): 396-9. PMID17325833. doi:10.1007/s00134-007-0556-8.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (septiembre de 2005). «Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death». N. Engl. J. Med.353 (13): 1332-41. PMID16192478. doi:10.1056/NEJMoa050935.
Vehar GA, Davie EW (febrero de 1980). «Preparation and properties of bovine factor VIII (antihemophilic factor)». Biochemistry19 (3): 401-10. PMID7356933. doi:10.1021/bi00544a001.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (junio de 2008). «Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)». Chest133 (6 Suppl): 160S-198S. PMID18574265. doi:10.1378/chest.08-0670.